(PRWEB) March 20, 2008
Ascent Scientific (http://www.ascentscientific.com) announced the addition of a novel potent Group III glutamate agonist to the Low-Cost Ligand range - aiding research into neurological disorders. This potent new tool is called L-thioAP4 and is two-fold more potent than the industry standard L-AP4, which is used by thousands of researchers all over the world.
Up until now, life science researchers have been using the analogue L-AP4 for their studies on glutamate receptors, neurological disorders and brain physiology. The new glutamate agonist L-thioAP4 has similar selectivity, but is two-fold more potent than L-AP4.
Steve Roome PhD, Commercial Director commented, "We are proud to be the first life science supplier to make this hugely exciting research tool commercially available. We have been delighted to work with the Centre National de la Recherche Scientifique (CNRS) in France, who have granted us permission to offer this tool to the scientific community."
Dr Francine C. Acher, Director of Research at the CNRS added "Because of its high potency, L-thioAP4 should become the most popular group-III mGluR agonist"
L-thioAP4 is the latest addition to the Low-Cost Ligand glutamate range, which includes L-AP4, D-AP5, Kainic Acid, MK-801, MPEP, MTEP and many other glutamate ligands.
Contact: Steve Roome, Commercial Director +44 (0)1934 624 695
About Ascent Scientific
The Ascent Scientific vision is to make it easy for life science researchers all over the world to do what they are best at -- research! Ascent Scientific makes this possible by offering a range of high quality receptor ligands and synthetic chemistry services at prices so low that as many researchers as possible will be able to afford them.